CLIMB BIO, INC. Payments to Acquire Marketable Securities
CLIMB BIO, INC. (CLYM) reported Payments to Acquire Marketable Securities of $127.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- CLIMB BIO, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $82.61M, a 300.63% increase year-over-year.
- CLIMB BIO, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $44.85M, a 23.65% decline year-over-year.
- CLIMB BIO, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $5.00M, a 91.73% decline year-over-year.
- CLIMB BIO, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $23.71M, a 66.97% decline year-over-year.
- CLIMB BIO, INC. payments to acquire marketable securities for fiscal 2025 was $108.08M, a 18.24% decline from fiscal 2024.
- CLIMB BIO, INC. payments to acquire marketable securities for fiscal 2024 was $132.20M, a 126.17% increase from fiscal 2023.
- CLIMB BIO, INC. payments to acquire marketable securities for fiscal 2023 was $58.45M, a 33.55% decline from fiscal 2022.
- CLIMB BIO, INC. payments to acquire marketable securities for fiscal 2022 was $87.96M, a 23.49% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $82.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $127.46M 10-Q · filed 2026-08-06 | $132.46M derived: sum of 3 quarters · filed 2026-08-06 | $156.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $44.85M 10-Q · filed 2026-05-07 | $49.85M derived: sum of 2 quarters · filed 2026-05-07 | $73.56M derived: sum of 3 quarters · filed 2026-05-07 | $94.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $28.71M derived: sum of 2 quarters · filed 2026-03-05 | $49.33M derived: sum of 3 quarters · filed 2026-08-06 | $108.08M 10-K · filed 2026-03-05 |
| 2025-09-30 | $23.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $44.33M derived: sum of 2 quarters · filed 2026-08-06 | $103.08M 10-Q · filed 2025-11-06 | $163.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $20.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $79.37M 10-Q · filed 2026-08-06 | $139.78M derived: sum of 3 quarters · filed 2026-08-06 | $211.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $58.75M 10-Q · filed 2026-05-07 | $119.16M derived: sum of 2 quarters · filed 2026-05-07 | $190.95M derived: sum of 3 quarters · filed 2026-05-07 | $190.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $60.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $132.20M derived: sum of 2 quarters · filed 2026-03-05 | $132.20M derived: sum of 3 quarters · filed 2026-03-05 | $132.20M 10-K · filed 2026-03-05 |
| 2024-09-30 | $71.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $71.79M derived: sum of 2 quarters · filed 2025-11-06 | $71.79M 10-Q · filed 2025-11-06 | $71.79M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $1.00K derived: sum of 3 quarters · filed 2025-08-12 | $2.46M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $1.00K derived: sum of 2 quarters · filed 2025-05-14 | $2.46M derived: sum of 3 quarters · filed 2025-05-14 | $41.00M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $2.46M derived: sum of 2 quarters · filed 2025-03-25 | $41.00M derived: sum of 3 quarters · filed 2025-03-25 | $58.45M 10-K · filed 2025-03-25 |
| 2023-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $41.00M derived: sum of 2 quarters · filed 2024-11-12 | $58.45M 10-Q · filed 2024-11-12 | $65.16M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $38.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $55.98M 10-Q · filed 2024-08-14 | $62.70M derived: sum of 3 quarters · filed 2024-08-14 | $109.44M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $17.45M 10-Q · filed 2024-05-15 | $24.17M derived: sum of 2 quarters · filed 2024-05-15 | $70.91M derived: sum of 3 quarters · filed 2024-05-15 | $79.83M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $53.46M derived: sum of 2 quarters · filed 2024-03-28 | $62.38M derived: sum of 3 quarters · filed 2024-03-28 | $87.96M 10-K · filed 2024-03-28 |
| 2022-09-30 | $46.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $55.67M derived: sum of 2 quarters · filed 2023-11-14 | $81.25M 10-Q · filed 2023-11-14 | $89.30M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $8.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $34.51M 10-Q · filed 2023-08-10 | $42.56M derived: sum of 3 quarters · filed 2023-08-10 | $149.48M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $25.58M 10-Q · filed 2023-05-11 | $33.63M derived: sum of 2 quarters · filed 2023-05-11 | $140.55M derived: sum of 3 quarters · filed 2023-05-11 | $140.55M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $8.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $114.97M derived: sum of 2 quarters · filed 2023-03-06 | $114.97M derived: sum of 3 quarters · filed 2023-03-06 | $114.97M 10-K · filed 2023-03-06 |
| 2021-09-30 | $106.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $106.92M derived: sum of 2 quarters · filed 2022-11-14 | $106.92M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |